Protagonist Therapeutics (PTGX) Other Non Operating Income (2016 - 2026)
Protagonist Therapeutics (PTGX) reported Other Non Operating Income of $53000.0 for Q1 2026, down 35.37% on a YoY basis from $82000.0 in Q1 2025, and up 235.9% sequentially from -$39000.0 in Q4 2025.
Protagonist Therapeutics (PTGX) Other Non Operating Income (2016 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 10 years of Other Non Operating Income data on file, last reported at $53000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 35.37% year-over-year to $53000.0; the trailing twelve-month figure through Mar 2026 stood at $83000.0 (up 101.79% YoY), and the FY2025 full-year result was $112000.0, up 102.36% from the prior year.
- Other Non Operating Income improved to $53000.0 in Q1 2026, from -$39000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $141000.0 in Q3 2024 to a low of -$5.0 million in Q4 2024.
- A 5-year average of -$286176.5 and a median of $13000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income soared 646.15% in 2022 and plunged 11390.91% in 2024, its largest moves.
- Tracing PTGX's Other Non Operating Income over 5 years: stood at $71000.0 in 2022, then plunged by 38.03% to $44000.0 in 2023, then sank by 11390.91% to -$5.0 million in 2024, then jumped by 99.21% to -$39000.0 in 2025, then jumped by 235.9% to $53000.0 in 2026.
- Business Quant data shows PTGX's Other Non Operating Income at $53000.0 in Q1 2026, -$39000.0 in Q4 2025, and $33000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | -4.97 Mn |
| Sep 30, 2024 | 141,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | -31,000.00 |
| Jun 30, 2023 | -19,000.00 |
| Mar 31, 2023 | -195,000.00 |
| Dec 31, 2022 | 71,000.00 |
| Sep 30, 2022 | -86,000.00 |
| Jun 30, 2022 | -78,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | -13,000.00 |
| Jun 30, 2021 | -57,000.00 |
| Mar 31, 2021 | -79,000.00 |